Robuta

Sponsor of the Day: Jerkmate
https://immatics.com/contact-us/ Contact Us | Immatics usimmatics https://immatics.com/ Immatics Apr 27, 2026 - Immatics combines the discovery of cancer targets with T cell receptor development to create Adoptive Cell Therapies and TCR Bispecifics. immatics https://wellington-partners.com/immatics-achieves-clinical-proof-of-concept-of-its-next-generation-tcr-bispecific-tcer-pipeline-with-data-on-ima402-prame-and-ima401-magea4-8-and-announces-next-development-steps/ Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline... Nov 24, 2025 - ALCESTER, England and BEVERLY, Massachusetts, 23 June 2021: Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology leader next generationimmaticsachievesclinicalproof